Oncology
Epithelial Tumor
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Epithelial Tumor is an early-stage landscape with 0 programs across 1 company. The most active players are Myeloid Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
5
clinical trials
Unknown status2 · 40%
Completed2 · 40%
Recruiting1 · 20%
Clinical Trials
Trial Activity
The Method ISET (Insulation by Size of Epithelial Tumor Cells)
Unknown status·—·N/A·NCT00818558·520 enrolled
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
Completed·—·Phase 1·NCT00004082
Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors
Unknown status·—·Phase 2·NCT03989830·53 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)